Absci Corporation

Ransi Somaratne Mudalinayake filed a late initial Form 3 as Chief Medical Officer and Head of R&D of Absci Corp; the triggering event date was March 3, 2026, but the form was submitted August 7, 2026 — approximately five months late. No securities are beneficially owned; both the direct and derivative security tables are empty. The form was signed by authorized representative Shelby Walker. This is a routine insider registration disclosure, delayed but administratively immaterial.

Absci Corporation entered into an underwriting agreement with Jefferies, J.P. Morgan, TD Securities, and Guggenheim to sell 13,495,277 shares of common stock at $7.41 per share. Net proceeds are estimated at ~$93.5 million after underwriting discounts and offering expenses, with closing expected June 25, 2026. Proceeds will fund advancement of ABS-201, Absci's AI-designed anti-PRLR antibody targeting androgenetic alopecia and endometriosis, plus general working capital. This is a material equity raise that dilutes existing shareholders but provides meaningful clinical-stage runway.

Absci Corporation is offering 13,495,277 shares of common stock at $7.41 per share under its existing shelf registration, raising ~$100 million gross (~$94 million net before expenses). Notably, Eli Lilly and Company is purchasing 5,398,111 shares (~$40 million) of the offering, with underwriters taking the remainder. Shares expected to deliver on or about June 25, 2026. The Lilly participation is strategically significant — a major pharma buyer at $40M validates Absci's AI drug design platform, even as the offering is dilutive to existing holders.

ABSI (ABSI) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on ratification of the independent auditor. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.